SAWC Fall: Oct 7-9, 2016; Las Vegas, NV
- Order Now
Medical grade maggot therapy for wound debridement coming to Canada.
Vancouver, BC and Irvine, CA —Superna Life Sciences and Monarch Labs announced today the initiation of a collaboration to seek marketing approval of Medical MaggotsTM (disinfected Phaenicia sericata larvae) in Canada. Medical Maggots are intended to be a prescription-only medical therapy used to debride (clean) non-healing wounds so that they can heal. After regulatory approval, the two companies plan to jointly promote and commercialize Medical MaggotsTM in Canada.
“We are very excited to have a Canadian partner for our proprietary Medical MaggotsTM and related wound care products. Canadian patients live in one of the few developed countries that still do not have access to approved medicinal maggots. Maggot therapy is a natural and inexpensive wound treatment with allowed use in many parts of the world including the United States and many parts of Europe. Having Superna Life Sciences as our partner will help expedite and facilitate access to this safe and efficacious medical therapy. We have seen significant interest among Canadian wound care professionals in maggot therapy and have been supplying our maggots under Special Access for Canadian patients,” said Ron Sherman, M.D., Laboratory Director and
Co-founder of Monarch Labs.
Positive Customer Impact
Several Canadian institutions have already benefited from using Monarch Labs’ Medical Maggots. “Using maggot debridement therapy, we have successfully treated patients in our institution who had non-healing wounds who would be treated for months otherwise with expensive antibiotics. When used appropriately, medical-grade maggots clear these wounds of dead and rotting tissue while stimulating healing,” said Lisa Helger, RN, a wound care professional at Burnaby Hospital in Burnaby, BC.
According to Christine Pearson, RN, a Community Wound Clinician at Vancouver Coastal Health in North Vancouver, BC, “With the forecasted rise in prevalence of diabetes among Canadians, we will see increased numbers of these patients with non-healing foot ulcers, putting them at heightened risk of amputations. Maggot debridement therapy may be able to reduce the amount of surgical debridement and amputations needed in the future in these patients.”
History of Maggot Debridement Therapy
Canadian patients have been supplied maggots on a compassionate use basis through Health Canada’s Special Access Program by Irvine, California-based Monarch Labs for the past few years. Superna and Monarch will work with Health Canada to file a submission for full approval so that all patients in Canada can readily have access to this important therapy. MDT has a long history with reports of humans using maggots for wound care since antiquity. Written reports of the efficacy of medicinal maggots date back to the American Civil War and World War I. Maggot therapy utilizes dressings with disinfected fly larvae on non-healing skin and soft-tissue wounds in order to clean and disinfect the area of dead, infected tissue. Debridement by maggots is selective to dying, necrotic tissue while sparing healthy tissue.
About Superna Life Sciences
Superna Life Sciences is a privately-held, Canadian company specializing in niche indications, orphan diseases, and supportive care cancer treatments. Superna currently markets Quadramet (Sm-153 EDTMP, radioisotope) for the treatment of metastatic bone pain in breast cancer, prostate cancer and other cancers. Superna also markets Caphosol, a non-prescription product for the treatment of severe mouth sores that result from chemotherapy or radiation treatments. Superna was founded in 2009 in Vancouver, BC. Please visit our website www.supernapharma.com for more information.
About Monarch Labs
Founded in 2005, Monarch Labs is the worldwide leader in “living medicine” products. Our medical products maintain health in a safe, effective, inexpensive and natural manner. We manufacture and distribute
Medical Maggots™ (disinfected Phaenicia sericata larvae). Medical Maggots™ are regulated by the Food and Drug Administration as a
prescription only medical device for treating non-healing wounds. Most private insurance and public health benefits payors reimburse maggot therapy. Monarch Labs’ products comply with good manufacturing practices and other regulatory requirements. Based in Irvine, CA, USA, Monarch Labs is developing new products including leech therapy for venous congestion and fecal microbiota transplantation for recurrent Clostridium difficile infections. Please visit www.monarchlabs.com for more information.
For more information, press only:
Public Relations and Inquiries: 604-630-1100 or email@example.com;